EDNRA and ovarian cancer: A β-arrestin biased ETA antagonist would be predicted to have benefit over a non-biased ETA antagonist in ovarian cancer as ETA/Gαs/cAMP activation of protein kinase A opposes the detrimental ETA/β-arrestin stimulated expression of cancer genes.